CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7 enrolled
Drug / intervention
Fusion closed loop glucose control systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05644730
NCT05644730N/ACompleted
CompareCT.gov

Demonstration of an Artificial Intelligence Based Closed Loop Glucose Control System as a Therapeutic Modality in Type 1 and Type 2 Diabetic Patients

Ideal Medical Technologies·interventional·Posted Dec 9, 2022·Updated Jul 17, 2025

In Brief

A clinical study evaluating Fusion closed loop glucose control system for Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2. Completed, enrolled 7 participants across 1 site.

Detailed Summary

This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting. The type 1 and type 2 diabetic subjects in this study will have their glucose controlled to a range of 100-140 mg/dL by a novel artificial intelligence based closed loop glucose control system for a period of 24 hours. The subjects will consume three standardized meals during the 24 hour study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
CountriesUnited States
CollaboratorsEmory University

Timeline

N/ACompletedFinished
2023202420252026
First PostedDec 9, 2022
Enrollment StartNov 8, 2022
Primary CompletionApr 21, 2023
Study CompletionJun 21, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.6 years ago

Interventions

Fusion closed loop glucose control systemdevice

The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.